Cabaletta Bio reports Q4/FY2023 financials; first patient dosed with CABA-201 in myositis

Cabaletta Bio, Inc.

Cash, cash equivalents and short-term investments $241.2M as of Dec 31, 2023, with runway into 1H26.
R&D expenses $17.4M (Q4) and $55.4M (FY2023); G&A $5.7M (Q4) and $19.2M (FY2023).
First patient dosed in Phase 1/2 RESET-Myositis trial; no CRS or ICANS observed in first 21 days.
Initial clinical data from RESET-Myositis and RESET-SLE expected in 1H24; longer-term follow-up in 2H24.
FDA granted Rare Pediatric Disease designation for CABA-201 in juvenile dermatomyositis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cabaletta Bio, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-073294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.